##plugins.themes.academic_pro.article.main##
Abstract
193 vaccinated children were observed for 1.5 years. At the age of 2–6 months, 30% of premature and 46% of children with congenital heart defects were vaccinated with the PCV7/PCV13 vaccine; at the age of 7–11 months, 52 and 40%, respectively. In 65% of cases, the PCV7/PCV13 vaccine was administered together with other vaccines in the national preventive vaccination schedule. The frequency of general post-vaccination reactions (increase in body temperature from 37.6 to 38.0°C) was 4%; no local reactions were recorded. No other adverse events were noted in the post-vaccination period.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Salomov Shoxabbos Nozimjon o’g’li, & Bustonov Sherzod. (2024). PNEUMOCOCCAL VACCINE VACCINATION IN CHILDREN WITH CONGENITAL HEART DEFECTS. American Journal of Technology and Applied Sciences, 21, 37–39. Retrieved from https://americanjournal.org/index.php/ajtas/article/view/1869